Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep apnea, insomnia services venture

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOS

0.00

  • Vivos Therapeutics entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned MSO targeting sleep apnea care in cardiac patients.
  • Vivos expects to hold at least 80% of AIM Florida. SPCVA would hold up to 20%, subject to definitive agreements and regulatory requirements.
  • Initial rollout targets Palm Beach County. One sleep optimization team is planned to serve about 250 patients per month.
  • Operating plan forecasts more than USD 6 million annual revenue per team with contribution margins near 50% once fully deployed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100903PRIMZONEFULLFEED9734857) on June 10, 2026, and is solely responsible for the information contained therein.